357 related articles for article (PubMed ID: 37706523)
1. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
Cai F; Zhang J; Gao H; Shen H
Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
[TBL] [Abstract][Full Text] [Related]
2. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
3. Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
Giordano Attianese GMP; Ash S; Irving M
Immunol Rev; 2023 Nov; 320(1):166-198. PubMed ID: 37548063
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
5. Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.
Noraldeen SAM; Rasulova I; Lalitha R; Hussin F; Alsaab HO; Alawadi AH; Alsaalamy A; Sayyid NH; Alkhafaji AT; Mustafa YF; Shayan SK
Med Oncol; 2023 Oct; 40(11):313. PubMed ID: 37779152
[TBL] [Abstract][Full Text] [Related]
6. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
7. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
[TBL] [Abstract][Full Text] [Related]
8. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
Johnson A; Townsend M; O'Neill K
Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
[TBL] [Abstract][Full Text] [Related]
10. Bright future or blind alley? CAR-T cell therapy for solid tumors.
Zhang K; Chen H; Li F; Huang S; Chen F; Li Y
Front Immunol; 2023; 14():1045024. PubMed ID: 36761757
[TBL] [Abstract][Full Text] [Related]
11. Hurdles to breakthrough in CAR T cell therapy of solid tumors.
Marofi F; Achmad H; Bokov D; Abdelbasset WK; Alsadoon Z; Chupradit S; Suksatan W; Shariatzadeh S; Hasanpoor Z; Yazdanifar M; Shomali N; Khiavi FM
Stem Cell Res Ther; 2022 Apr; 13(1):140. PubMed ID: 35365241
[TBL] [Abstract][Full Text] [Related]
12. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
13. Current perspectives on resistance to chimeric antigen receptor T-cell therapy and strategies to improve efficacy in B-cell lymphoma.
Ong SY; Chen Y; Tan MSY; Ho AYL; Hwang WYK; Lim FLWI
Eur J Haematol; 2024 Feb; 112(2):144-152. PubMed ID: 36987995
[TBL] [Abstract][Full Text] [Related]
14. Engineering chimeric antigen receptor T cells for solid tumour therapy.
Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
[TBL] [Abstract][Full Text] [Related]
15. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
16. CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity.
Tan JY; Low MH; Chen Y; Lim FLWI
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805933
[TBL] [Abstract][Full Text] [Related]
17. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity.
Boulch M; Cazaux M; Loe-Mie Y; Thibaut R; Corre B; LemaƮtre F; Grandjean CL; Garcia Z; Bousso P
Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33771887
[TBL] [Abstract][Full Text] [Related]
18. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
20. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]